{"id":"W289544031","doi":"10.1200/jco.2014.32.15_suppl.5010","title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":231,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary; Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"","keywords":"Medicine; Tolerability; Nivolumab; Pazopanib; Sunitinib; Renal cell carcinoma; Internal medicine; Peripheral edema; Urology; Oncology; Gastroenterology; Surgery; Adverse effect; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003114192,0.0003357273,0.002310209,0.000531393,0.00004185035,0.00001819575,0.0002386859,0.0002826304,0.000131736],"category_scores_gemma":[0.001240119,0.000197413,0.000239128,0.0004795785,0.0002543717,0.0002211498,0.00005384371,0.001377601,0.00002484099],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006376236,"about_ca_system_score_gemma":0.001860303,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000182906,"about_ca_topic_score_gemma":0.001138396,"domain_scores_codex":[0.9941527,0.001324961,0.002815945,0.0004012401,0.0008172119,0.0004879972],"domain_scores_gemma":[0.9940204,0.002335914,0.002132784,0.0003563368,0.0006787616,0.0004757844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02768623,0.01003029,0.9256878,0.0001170536,0.0001627629,0.003271562,0.0002572041,0.0001152316,0.00005571321,0.00005847689,0.0003638502,0.03219383],"study_design_scores_gemma":[0.06623832,0.08890201,0.8408151,0.000316004,0.0005004075,0.0003443333,0.0002057524,0.0002609881,0.0003762373,0.00006693967,0.001773552,0.0002003467],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945035,0.00007039904,0.0001410578,0.001182563,0.0002848357,0.0006807652,0.000003723603,0.00000971978,0.003123458],"genre_scores_gemma":[0.9938077,0.0000462784,0.004805939,0.0007510345,0.0002059476,0.00001616565,0.00002327962,0.00004903546,0.0002945914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08487269,"threshold_uncertainty_score":0.8050268,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07842517922211807,"score_gpt":0.3731375417796043,"score_spread":0.2947123625574863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}